RxDoctor Payments DataLook up a doctor →

David Stickler, MD

Neurology · North Charleston, SCNPI 1699711945

Payments from drug & device makers

$1,204,323in general payments, 2019–2025

Across 323 payments — averaging $3728.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$359K
  • AbbVie$290K
  • Adamas Pharmaceuticals, Inc.$139K
  • Amgen$94K
  • AstraZeneca$81K
  • Lexicon Pharmaceuticals, Inc.$71K
  • plus $170K from 35 others
$1,076in research payments, 2019–2025

Across 1 payment — averaging $1076.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

What the payments were for

  • Speaking & faculty fees$131%
  • Food & beverage$2,16299%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,204,323 in reported general payments places this provider in the 95th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$112,167
Medicare patients
432
Services billed
1,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5052$397,106
BriviactBrivaracetam17$39,019
GlatopaGlatiramer Acetate14$37,632
QuliptaAtogepant22$26,337
Aimovig AutoinjectorErenumab-Aooe24$21,728
Pyridostigmine Bromide58$4,782
Lacosamide21$4,045
Oxcarbazepine22$2,315
Carbidopa-LevodopaCarbidopa/Levodopa76$2,313
Mycophenolate Mofetil32$2,183
Scopolamine24$2,091
Azathioprine32$2,090
DilantinPhenytoin Sodium Extended12$1,942
Memantine Hcl31$1,763
Levetiracetam44$1,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$127$39,01917 claims
AbbVieQulipta$290,411$26,33722 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$43$6,96590 claims
Upsher-smith Laboratories LLCTopiramate$50$60539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 270 neurology providers in South Carolina.

Other neurology in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →